Is Opexa Therapeutics Inc (NASDAQ:OPXA) Qualified?

Posted by Lynn Eisler October 2, 2013 0 Comment 1387 views


On 30 September, Opexa Therapeutics Inc (NASDAQ:OPXA) announced that the President and CEO of the company, Neil K Warma had received an invitation to be a panel member at the 9th-Annual Burrill Personalized Medicine Meeting. This event was held from 30 September – 1October 2013 at San Francisco’s Bentley Reserve & Conference Center

Mr. Warma joined numerous experts in the personalized medicine filed in discussions of the different advances that the industry has made. Topics like the implications of drug development were also discussed.

Tuesday’s trading

In Tuesday’s trading, Opexa Therapeutics Inc (NASDAQ:OPXA) dropped 7.76%. The shares opened at a price of $2.21, climbed to an intraday high of $2.24 and dipped to a close of $2.02. Approximately 1.20 million shares were traded on Tuesday while an average volume of 1.12 million shares were traded over a 30 day period. The 52-week low of the company’s shares is $1.07 and its 52-week high is $5.19. The company has a market capitalization of $40.63 million

About the company

Opexa Therapeutics Inc (NASDAQ:OPXA) is a bio-pharma company. It is involved in developing various personalized cellular-therapies that have the potential to treat illnesses such as multiple sclerosis (MS). All these therapies are based on the company’s T-cell technology. Tovaxin, is Opexa Therapeutics Inc (NASDAQ:OPXA’s) core product candidate. This is a personalized T-cell therapeutic-vaccine that has been licensed from the Baylor College of Medicine.

It is in clinical-development for treatment of MS. Tovaxin is the T-cell immunotherapy that is slated to enter Phase-III clinical-development for treating relapsing remitting MS (RR-MS). In 2011 November, Opexa Therapeutics Inc (NASDAQ:OPXA) re-acquired the stem-cell assets from Novartis Pharmaceuticals. Tovaxin is a personalized- therapy that is specifically customized to each patient’s disease-profile. It is manufactured using the method of production that is used in the production of patient-specific T cell immunotherapy.


About Lynn Eisler

Lynn Eisler is a national news reporter focusing on economic issues, data analysis and the financial health of state and local governments. Lynn has been honored with the H.L. Mencken Award for Investigative Reporting, the Champion of Justice Award for reporting on the drug war, and the John Hancock Award for business reporting. Lynn was also a Knight Medical School Fellow at the University of Michigan.

View all post by Lynn Eisler Visit author's website

Write Your Comment